The opioid receptor like-1 receptor agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one) produces a discriminative stimulus in rats distinct from that of a mu, kappa, and delta opioid receptor agonist cue

The Journal of Pharmacology and Experimental Therapeutics
Matthew D Recker, G A Higgins

Abstract

Male Wistar rats were trained to discriminate either the opioid receptor like (ORL)-1 receptor agonist Ro 64-6198 (1S,3aS-8-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one) or morphine from saline using a two-choice, food reinforced, operant procedure. Acquisition of Ro 64-6198 discrimination was relatively slow (mean trials to criterion 113 +/- 6), and a final 4 mg/kg dose (initial training dose 2 mg/kg) was required to establish appropriate stimulus control. In comparison, a separate group of rats attained a morphine (2 mg/kg) discrimination in 44 +/- 4 trials. In tests of substitution, Ro 64-6198 produced a dose-related generalization to its own cue (ED(50) of 1.1 mg/kg i.p.), yet only weakly generalized to the morphine cue (19% at 10 mg/kg i.p.). In contrast, morphine generalized completely to the morphine cue (ED(50) of 0.7 mg/kg s.c.), yet only partially generalized to the Ro 64-6198 cue (40% at 6 mg/kg s.c.). The kappa opioid receptor agonist U50,488 [trans-3,4-dichloro-N-methyl-N(2-[1-pyrrolidinyl]cyclohexyl) benzeneacetamide methanesulfonate] (0.3-6 mg/kg s.c.) and the delta opioid receptor agonist SNC-80 [(+)-4-[(alphaR)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxyben...Continue Reading

References

Nov 10, 1976·Psychopharmacology·H E Shannon, S G Holtzman
Apr 1, 1997·Psychopharmacology·S G Holtzman
Feb 3, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·P BroquaS G Dahl
Jun 22, 1999·Brain Research·N P MurphyN T Maidment
Apr 1, 2000·British Journal of Pharmacology·G Calo'D Regoli
Apr 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·F JenckG Kilpatrick
Sep 12, 2000·European Journal of Pharmacology·R CiccocioppoM Massi
Mar 20, 2002·Pharmacology, Biochemistry, and Behavior·J M KhannaH Kalant
Mar 22, 2002·The European Journal of Neuroscience·G A HigginsA J Grottick
Apr 4, 2002·Neuroreport·Gwenaëlle Le PenFrançois Jenck
Apr 23, 2003·Trends in Pharmacological Sciences·Solomon H Snyder, Gavril W Pasternak
May 22, 2003·Drug and Alcohol Dependence·Robert S MansbachSidney H Schnoll
Jan 17, 2004·Psychopharmacology·Mark S TodtenkopfWilliam A Carlezon

❮ Previous
Next ❯

Citations

Jul 13, 2005·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Mellar P Davis
Dec 23, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Guy A HigginsPaul J Fletcher
Dec 5, 2012·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Leo B SilenieksGuy A Higgins
Jan 24, 2016·The Journal of Pharmacology and Experimental Therapeutics·Phillip A SacconeJames H Woods
Jul 26, 2005·Peptides·Richard J Bodnar, Gad E Klein
Dec 13, 2017·International Review of Psychiatry·Savannah TollefsonRajesh Narendran
Jul 6, 2018·The Journal of Toxicological Sciences·Atsushi FujiwaraAkihito Shimoi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.